乳腺癌仍然是一个重大的全球健康挑战，推动了对有效治疗策略的需求。顺铂是一种强效化疗药物，广泛用于乳腺癌治疗。然而，其有效性常常受到全身毒性和耐药性发展的限制。这篇综述研究了影响顺铂反应和耐药性的分子因素，为科学界提供了重要的见解。它强调了了解顺铂耐药性的遗传和表观遗传因素的重要性，这可能会导致更加个性化的治疗方法。此外，该综述还探索了对抗顺铂耐药性的创新策略，包括联合疗法、基于纳米颗粒的药物输送系统和靶向疗法。这些方法正在深入研究中，有望提高乳腺癌的治疗效果。这一全面的讨论是推进乳腺癌治疗和解决顺铂耐药性挑战的宝贵资源。版权所有 © 2024。由 Elsevier B.V. 出版。

Breast cancer continues to be a major global health challenge, driving the need for effective therapeutic strategies. Cisplatin, a powerful chemotherapeutic agent, is widely used in breast cancer treatment. However, its effectiveness is often limited by systemic toxicity and the development of drug resistance. This review examines the molecular factors that influence cisplatin response and resistance, offering crucial insights for the scientific community. It highlights the significance of understanding cisplatin resistance's genetic and epigenetic contributors, which could lead to more personalized treatment approaches. Additionally, the review explores innovative strategies to counteract cisplatin resistance, including combination therapies, nanoparticle-based drug delivery systems, and targeted therapies. These approaches are under intensive investigation and promise to enhance breast cancer treatment outcomes. This comprehensive discussion is a valuable resource to advance breast cancer therapeutics and address the challenge of cisplatin resistance.Copyright © 2024. Published by Elsevier B.V.